The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

The recent trial regarding the discontinued heartburn drug Zantac, which allegedly causes cancer, ended in a hung jury. The ...

The trial met its primary endpoint, showing a meaningful objective response rate and a tolerable safety profile for ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

Boehringer Ingelheim today announced that the FIBRONEER-IPF trial met its primary endpoint, which was the absolute change ...

A Chicago jury failed to reach a verdict in the latest Zantac cancer trial involving Boehringer Ingelheim. Plaintiff Ronald ...

Boehringer Ingelheim pivotal phase-III FIBRONEER-IPF study of nerandomilast meets primary endpoint: Ingelheim, Germany Tuesday, September 17, 2024, 13:00 Hrs [IST] Boehringer Inge ...

The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for Biomedical Artificial Intelligence (AI) based on a € 150 million funding from the ...